Showing results (2221-2230 of 2,349) with videos related to

Sort By:
Pageof 235
International Journal of Radiation Oncology, Biology, Physics|November 6, 2018
Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized TrialTerence T Sio, Pamela J Atherton, Levi D Pederson, et al.
Zhonghua Nei Ke Za Zhi|June 30, 2020
[Practice guideline for patients with hyperuricemia/gout]Y F Huang, K H Yang, S H Chen, et al.
Endocrinology|January 1, 1997
Neuropeptide Y induced feeding in the rat is mediated by a novel receptorD O'Shea, D G Morgan, K Meeran, et al.
JAMA Otolaryngology-- Head & Neck Surgery|August 29, 2024
Cancer in Patients With Incidental Asymmetric Oropharynx Positron Emission Tomography UptakeMichael F Armstrong, Brian J Burkett, Thomas J O'Byrne, et al.
Practical Radiation Oncology|October 29, 2021
Outcomes and Patterns of Recurrence for Anaplastic Thyroid Cancer Treated With Comprehensive ChemoradiotherapyRobert W Gao, Robert L Foote, Yolanda I Garces, et al.
Journal of Medical Virology|November 28, 2025
Circulating Human Papillomavirus DNA-Liquid Biopsy in Head and Neck CancersTyler Jahraus, Andrew Koempel, Catherine Haring, et al.
Scientific Reports|September 17, 2024
Perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) morphologic, qualitative, semiquantitative, and radiomics features predicting undifferentiated pleomorphic sarcoma (UPS) treatment responseR F Valenzuela, E Duran-Sierra, M Canjirathinkal, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|October 1, 2013
Monitoring the health-related labelling of foods and non-alcoholic beverages in retail settingsM Rayner, A Wood, M Lawrence, et al.
The Review of Scientific Instruments|September 29, 2023
A versatile control program for positioning and shooting targets in laser-plasma experimentsP J Wang, D H Wang, Y Gao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
Pageof 235